Profil
Brooks Rahmer is currently the Head-Investors Relations Contact at Rocket Pharmaceuticals, Inc. He previously worked as the Investor Relations Contact at MyoKardia, Inc. from 2019 to 2021.
Postes actifs de Brooks Rahmer
| Sociétés | Poste | Début |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Anciens postes connus de Brooks Rahmer
| Sociétés | Poste | Fin |
|---|---|---|
| MYOKARDIA, INC. | Investor Relations Contact | 01/01/2021 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
